← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Seer, Inc. (SEER) 10-Year Financial Performance & Capital Metrics

SEER • • Industrial / General
HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring
AboutSeer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.Show more
  • Revenue $14M -8.1%
  • EBITDA -$94M +5.5%
  • Net Income -$87M -0.4%
  • EPS (Diluted) -1.39 -3.0%
  • Gross Margin 48.99% +413.2%
  • EBITDA Margin -673.44% -2.9%
  • Operating Margin -717.72% -3.8%
  • Net Margin -620.91% -9.3%
  • ROE -23.91% -16.9%
  • ROIC -21.28% -10.4%
  • Debt/Equity 0.08 +11.3%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 160.6%
  • ✓Share count reduced 2.4% through buybacks
  • ✓Trading at only 0.4x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y160.62%
3Y29.69%
TTM14.49%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM4%

EPS CAGR

10Y-
5Y-
3Y-
TTM-3.08%

ROCE

10Y Avg-21.06%
5Y Avg-19.32%
3Y Avg-22.94%
Latest-25.86%

Peer Comparison

Diagnostics & Immune Monitoring
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
TECHBio-Techne Corporation10.9B69.96152.095.23%6.41%3.97%2.35%0.23
SPRYARS Pharmaceuticals, Inc.1.1B11.09142.002970.63%-56.06%-54.21%1.18%0.00
VCYTVeracyte, Inc.3.24B41.00132.2623.46%6.12%2.41%1.97%0.04
CSBRChampions Oncology, Inc.99.56M7.1721.7313.54%4.32%59.65%7.03%1.62
MDXGMiMedx Group, Inc.851.59M5.7520.548.52%10.38%17.09%7.58%0.13
LTRNLantern Pharma Inc.39.26M3.51-0.00-197.36%0.01
SEERSeer, Inc.107.44M1.91-1.37-8.13%-486.02%-29.19%0.08
IMDXInsight Molecular Diagnostics Inc.189.76M6.62-1.4225.15%-13.81%-14.81%

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+0116K656K6.39M14.69M15.18M13.95M
Revenue Growth %--4.66%8.75%1.3%0.03%-0.08%
Cost of Goods Sold+100K701K1.61M6.77M14.3M13.73M7.12M
COGS % of Revenue-6.04%2.45%1.06%0.97%0.9%0.51%
Gross Profit+-100K-585K-950K-374K384K1.45M6.83M
Gross Margin %--5.04%-1.45%-0.06%0.03%0.1%0.49%
Gross Profit Growth %--4.85%-0.62%0.61%2.03%2.77%3.71%
Operating Expenses+6.66M16.3M32.7M71.32M98.43M106.39M106.93M
OpEx % of Revenue-140.5%49.85%11.15%6.7%7.01%7.67%
Selling, General & Admin2.98M4.61M15.36M42.2M52.63M58.95M56.57M
SG&A % of Revenue-39.71%23.42%6.6%3.58%3.88%4.06%
Research & Development3.68M11.69M17.34M29.12M45.8M47.44M50.59M
R&D % of Revenue-100.79%26.43%4.55%3.12%3.12%3.63%
Other Operating Expenses000000-223K
Operating Income+-6.76M-16.88M-33.65M-71.7M-98.04M-104.94M-100.1M
Operating Margin %--145.54%-51.29%-11.21%-6.68%-6.91%-7.18%
Operating Income Growth %--1.5%-0.99%-1.13%-0.37%-0.07%0.05%
EBITDA+-6.66M-16.18M-32.04M-68.13M-92.14M-99.36M-93.92M
EBITDA Margin %--139.5%-48.85%-10.66%-6.27%-6.54%-6.73%
EBITDA Growth %--1.43%-0.98%-1.13%-0.35%-0.08%0.05%
D&A (Non-Cash Add-back)100K701K1.61M3.56M5.9M5.58M6.18M
EBIT-6.31M-16.03M-32.77M-71.17M-92.97M-86.28M-100.1M
Net Interest Income+451K845K883K304K4.6M17.76M16.67M
Interest Income451K850K883K326K4.6M17.76M16.67M
Interest Expense05K022K000
Other Income/Expense451K845K874K527K5.08M18.66M13.6M
Pretax Income+-6.31M-16.04M-32.77M-71.17M-92.97M-86.28M-86.5M
Pretax Margin %--138.26%-49.96%-11.13%-6.33%-5.68%-6.2%
Income Tax+00000098K
Effective Tax Rate %1%1%1%1%1%1%1%
Net Income+-6.31M-16.04M-32.77M-71.17M-92.97M-86.28M-86.6M
Net Margin %--138.26%-49.96%-11.13%-6.33%-5.68%-6.21%
Net Income Growth %--1.54%-1.04%-1.17%-0.31%0.07%-0%
Net Income (Continuing)-6.31M-16.04M-32.77M-71.17M-92.97M-86.28M-86.6M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-0.29-0.26-0.51-1.13-1.42-1.35-1.39
EPS Growth %-0.1%-0.96%-1.22%-0.26%0.05%-0.03%
EPS (Basic)-0.29-0.26-0.51-1.13-1.42-1.35-1.39
Diluted Shares Outstanding21.45M60.91M60.91M60.86M62.43M63.85M62.35M
Basic Shares Outstanding21.45M60.91M60.91M60.86M62.43M63.85M62.35M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+31.21M86.81M433.13M411.7M434.98M330.51M253.32M
Cash & Short-Term Investments30.95M86.02M431.86M400.07M421.24M316.22M236.41M
Cash Only30.95M17.48M333.58M232.81M53.21M32.5M40.75M
Short-Term Investments068.53M98.28M167.26M368.03M283.73M195.66M
Accounts Receivable69K326K262K4.14M7.02M6.72M6.23M
Days Sales Outstanding-1.03K145.78236.56174.43161.46163.02
Inventory00551K4.14M4.63M4.49M7.44M
Days Inventory Outstanding--125.23223.54118.09119.36381.47
Other Current Assets00452K02.1M3.08M3.25M
Total Non-Current Assets+2.48M6.43M9.19M127.44M52.95M105.76M113.27M
Property, Plant & Equipment2.36M5.69M8.44M33.23M46.41M47.37M41.37M
Fixed Asset Turnover-0.02x0.08x0.19x0.32x0.32x0.34x
Goodwill0000000
Intangible Assets0000000
Long-Term Investments00343K93.19M5.16M56.86M63.1M
Other Non-Current Assets124K743K407K1.02M1.38M1.53M8.8M
Total Assets+33.7M93.24M442.32M539.14M487.93M436.27M366.6M
Asset Turnover-0.00x0.00x0.01x0.03x0.03x0.04x
Asset Growth %-1.77%3.74%0.22%-0.09%-0.11%-0.16%
Total Current Liabilities+3.69M3.81M8.09M13.42M12.58M13.22M15.33M
Accounts Payable2.63M701K2.12M3.79M2.1M1.37M4.62M
Days Payables Outstanding9.58K365480.68204.3453.736.41237.06
Short-Term Debt000002.29M2.31M
Deferred Revenue (Current)0175K250K376K133K206K408K
Other Current Liabilities344K1.6M2.86M4.73M6.35M2.73M1.54M
Current Ratio8.46x22.75x53.51x30.67x34.57x25.00x16.53x
Quick Ratio8.46x22.75x53.44x30.36x34.20x24.66x16.04x
Cash Conversion Cycle---209.68255.76238.83244.41307.43
Total Non-Current Liabilities+30K1.74M2.62M22.8M28.35M26.14M23.7M
Long-Term Debt0000000
Capital Lease Obligations00022.46M28.03M25.96M23.65M
Deferred Tax Liabilities0000000
Other Non-Current Liabilities30K1.74M2.62M341K320K179K48K
Total Liabilities3.72M5.56M10.71M36.22M40.94M39.37M39.03M
Total Debt+00023.32M29.87M28.26M25.96M
Net Debt-30.95M-17.48M-333.58M-209.49M-23.33M-4.24M-14.79M
Debt / Equity---0.05x0.07x0.07x0.08x
Debt / EBITDA-------
Net Debt / EBITDA-------
Interest Coverage--3376.60x--3258.91x---
Total Equity+29.98M87.68M431.61M502.92M446.99M396.9M327.57M
Equity Growth %-1.93%3.92%0.17%-0.11%-0.11%-0.17%
Book Value per Share1.401.447.098.267.166.225.25
Total Shareholders' Equity29.98M87.68M431.61M502.92M446.99M396.9M327.57M
Common Stock001K1K1K1K1K
Retained Earnings-6.55M-22.59M-55.36M-126.53M-219.5M-305.77M-392.37M
Treasury Stock0000000
Accumulated OCI-31K24K54K-536K-1.25M-192K136K
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-4.65M-13.07M-20.83M-46.35M-60.78M-59.06M-46.11M
Operating CF Margin %--112.7%-31.75%-7.25%-4.14%-3.89%-3.31%
Operating CF Growth %--1.81%-0.59%-1.23%-0.31%0.03%0.22%
Net Income-6.31M-16.04M-32.77M-71.17M-92.97M-86.28M-86.6M
Depreciation & Amortization31K701K1.61M2.56M3.94M5.58M6.18M
Stock-Based Compensation672K1.56M7.35M25.93M33.67M34.42M28.21M
Deferred Taxes0-259K01.2M000
Other Non-Cash Items549K5K271K1M1.66M-10.07M6.25M
Working Capital Changes953K961K2.72M-5.87M-7.09M-2.72M-144K
Change in Receivables-69K-257K64K-2.5M-2.87M302K487K
Change in Inventory0257K-551K-3.59M-1.59M-1.95M-2.67M
Change in Payables323K218K912K1.6M-1.55M-987K3.35M
Cash from Investing+-168K-72.38M-34.56M-170.88M-122.72M37.9M65.86M
Capital Expenditures-168K-4.13M-4.53M-6.92M-10.27M-7.31M-3.58M
CapEx % of Revenue-35.61%6.91%1.08%0.7%0.48%0.26%
Acquisitions-------
Investments-------
Other Investing0-68.25M0-163.96M170K0343K
Cash from Financing+29.95M72.33M371.49M116.63M3.89M452K-11.49M
Debt Issued (Net)-------
Equity Issued (Net)-------
Dividends Paid0000000
Share Repurchases-------
Other Financing29.95M406K1.26M13.71M3.91M465K321K
Net Change in Cash-------
Free Cash Flow+-4.82M-17.2M-25.36M-53.27M-71.05M-66.37M-49.69M
FCF Margin %--148.31%-38.66%-8.33%-4.84%-4.37%-3.56%
FCF Growth %--2.57%-0.47%-1.1%-0.33%0.07%0.25%
FCF per Share-0.22-0.28-0.42-0.88-1.14-1.04-0.80
FCF Conversion (FCF/Net Income)0.74x0.82x0.64x0.65x0.65x0.68x0.53x
Interest Paid0000000
Taxes Paid000645K232K0154K

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)-21.04%-27.26%-12.62%-15.23%-19.57%-20.45%-23.91%
Return on Invested Capital (ROIC)--36.59%-30%-27.47%-20.51%-19.28%-21.28%
Gross Margin--504.31%-144.82%-5.85%2.61%9.54%48.99%
Net Margin--13825.86%-4996.19%-1113.06%-633.07%-568.28%-620.91%
Debt / Equity---0.05x0.07x0.07x0.08x
Interest Coverage--3376.60x--3258.91x---
FCF Conversion0.74x0.82x0.64x0.65x0.65x0.68x0.53x
Revenue Growth--465.52%874.7%129.67%3.38%-8.13%

Revenue by Segment

202120222023
Grant223K-1.1M
Grant Growth---
Product3.58M8.56M-
Product Growth-139.22%-
Related Party2.32M5.21M-
Related Party Growth-125.08%-
Service500K913K-
Service Growth-82.60%-
Grant and Other-808K-
Grant and Other Growth---

Frequently Asked Questions

Growth & Financials

Seer, Inc. (SEER) reported $16.3M in revenue for fiscal year 2024.

Seer, Inc. (SEER) saw revenue decline by 8.1% over the past year.

Seer, Inc. (SEER) reported a net loss of $79.3M for fiscal year 2024.

Dividend & Returns

Seer, Inc. (SEER) has a return on equity (ROE) of -23.9%. Negative ROE indicates the company is unprofitable.

Seer, Inc. (SEER) had negative free cash flow of $46.1M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.